• Biodesix Inc BDSX.OQ reported a quarterly adjusted loss of 6 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -10 cents. The mean expectation of six analysts for the quarter was for a loss of 7 cents per share. Wall Street expected results to range from -7 cents to -5 cents per share.

• Revenue rose 39.3% to $20.43 million from a year ago; analysts expected $19.88 million.

• Biodesix Inc's reported EPS for the quarter was a loss of 6 cents​.

• The company reported a quarterly loss of $8.25 million.

• Biodesix Inc shares had fallen by 48.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the healthcare facilities & services peer group is also "buy"

Wall Street's median 12-month price target for Biodesix Inc is $3.00

This summary was machine generated from LSEG data March 4 at 12:28 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)